| Dominique Enriquez, | |
|
800 Palm Ave, Imperial Beach, CA 91932-1529 | |
| (619) 424-8989 | |
| Not Available |
| Full Name | Dominique Enriquez |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 800 Palm Ave, Imperial Beach, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396499927 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 85553 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dominique Enriquez, 1888 Cobblecreek St, Chula Vista, CA 91913-3917 Ph: () - | Dominique Enriquez, 800 Palm Ave, Imperial Beach, CA 91932-1529 Ph: (619) 424-8989 |
News Archive
MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.
Vanderbilt University scientists have found evidence that the insulin-secreting beta cells of the pancreas, which are either killed or become dysfunctional in the two main forms of diabetes, have the capacity to regenerate.
Clinical Data, Inc. today announced that the Company has received two grants totaling nearly $500,000 under the Qualifying Therapeutic Discovery Project.
MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.
Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.
› Verified 9 days ago
Marianela Vasquez-sosa, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 570 10th St, Imperial Beach, CA 91932 Phone: 619-942-3110 | |
Dr. Fady Zakko, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 800 Palm Ave, Imperial Beach, CA 91932 Phone: 619-424-8989 | |
Jason Oh, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 800 Palm Ave, Imperial Beach, CA 91932 Phone: 619-424-8989 Fax: 619-424-9614 | |
Veronica Cuevas, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 800 Palm Ave, Imperial Beach, CA 91932 Phone: 619-424-8989 |